(CercleFinance.com) – bioMérieux soars by almost 8% after an activity update for the in vitro diagnostics specialist for the first three months of the year, accompanied by the presentation of its strategic plan and its objectives at five years old.
In line with the consensus, its turnover stood at 965 million euros for the first quarter of 2024, up 9.8% at constant exchange rates and scope, allowing it to confirm its objectives for the whole year.
Furthermore, bioMérieux has indicated that it is targeting organic growth in turnover of 7% on an annual average over 2024-28 and a contributing ROC of 20% of turnover in 2028, objectives which ‘would rather be at the high end of expectations’, according to Oddo BHF.
‘First quarter sales are satisfactory and the elements relating to the CMD offer an additional degree of visibility which, in a DCF approach, should rather provide a little consensus material to be constructive,’ adds the research office.